Intraoperative radiotherapy for glioblastoma: an international pooled analysis

Glioblastoma (GB) represents the most frequent primary malignancy of the brain in adults, accounting for more than half of all gliomas [1]. Survival times are still narrow and range between 1 and 3  years [2–6]. Even patients with favorable risk factors, such as young age, high Karnofsky performance status (KPS) and hypermethylation of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter suffer from tumor recurrence, usually occurring 14–17 months after therapy [2,6].

Source: Radiotherapy and Oncology - October 15, 2019 Category: Radiology Authors: Gustavo R. Sarria, Elena Sperk, Xiaodi Han, Gustavo J. Sarria, Frederik Wenz, Stefanie Brehmer, Bing Fu, Siming Min, Hongjun Zhang, Shusen Qin, Xiaoguang Qiu, Daniel H änggi, Yasser Abo-Madyan, David Martinez, Carla Cabrera, Frank A. Giordano Tags: Original Article Source Type: research